HK Stock MarketDetailed Quotes

03737 ZHONGZHIPHARM

Watchlist
  • 0.910
  • +0.020+2.25%
Not Open Nov 7 16:08 CST
785.88MMarket Cap6.45P/E (TTM)

About ZHONGZHIPHARM Company

Founded in 1993, China Zhi Pharmaceutical Group is a private technology enterprise integrating scientific research, production and sales of proprietary medicines, Chinese medicine tablets, health products, and pharmaceutical retail chains. It has five subsidiaries of Zhongshan Hang Seng Pharmaceutical Co., Ltd., Zhongshan Zhongzhi Traditional Chinese Medicine Tablet Co., Ltd., Zhongshan Zhongzhi Pharmacy Chain Co., Ltd., Zhongshan Zhongzhi Pharmaceutical (Hong Kong) Co., Ltd., and Zhongshan Zhongzhi Food Technology Co., Ltd. It has a number of designated procurement bases for Chinese herbal medicines, and a complete pharmaceutical production and management industry chain. After years of development, Zhongzhi Pharmaceutical has embarked on a path of collaborative development of production, learning, and research. The company is committed to the innovative development path of traditional Chinese medicine, continuously improving the quality standards of existing proprietary Chinese medicine products, developing new proprietary Chinese medicine products, and developing new categories of safe and healthy traditional Chinese medicine tablet products with independent intellectual property rights; it is committed to cultivating various types of scientific and technological talents, and has successively established “science and technology service stations”, “postdoctoral workstations”, and “academician workstations”; it is committed to the construction of science and technology platforms and has carried out in-depth and wide-ranging cooperation with scientific research institutes, and has successively set up “industry-academia demonstration bases”, “innovative traditional Chinese medicine research and development demonstration bases”, “innovative Chinese medicine research and development demonstration bases”, “innovative Chinese medicine research and development demonstration bases”, “” “innovative Chinese medicine research and development demonstration bases”, “” “R&D demonstration bases for innovative traditional Chinese medicines”, and “R&D demonstration bases for innovative traditional Chinese medicines”, “R&D demonstration bases for innovative traditional Chinese medicines”, “” “R&D demonstration bases for innovative Chinese medicines”, and “R&D demonstration bases for innovative Chinese medicines”, “R&D demonstration bases for innovative traditional Chinese medicines”, “” “Graduate student in traditional Chinese pharmacy “Innovative Training Base”, etc., received national approval to build the “National Administration of Traditional Chinese Medicine Key Research Laboratory for Traditional Chinese Medicine Tablet Technology and Application” in 2014. An enterprise's strong team of scientific and technological talents and platforms is the foundation for strengthening the building of product strength and brand strength. The Zhongzhi Traditional Chinese Medicine Tablet is a brand new fourth-generation traditional Chinese medicine tablet. It has the high-end, convenient, and trendy characteristics of modern innovative traditional Chinese medicine. It is a new high-end health category manufactured by applying a patented additive-free molding technology based on modern traditional Chinese medicine ultrafine powder technology. It is the core variety of traditional Chinese medicine innovated by China Intelligence. Zhongzhi Breaking the Wall has a number of independent intellectual property rights and patents, and its level of technology is leading in the industry. In 2007, the Zhongzhi Traditional Chinese Medicine Wall-Breaking Drink series products were selected as key new product planning projects in Guangdong Province; in 2010, the Chinese Medicine Wall-Breaking Drink Project was selected for the national torch program. Subsequently, the company became a pilot production unit and industry standard setting unit for traditional Chinese medicine tablets in Guangdong Province. “Intelligent creation of a healthy life” is the core value of Zhongzhi. It guides China and Chile's commitment to improving and breaking through the modern engineering technology of proprietary Chinese medicines, Chinese medicine tablets and health products. China Zhi's innovative technology and scientific and technological achievements in traditional Chinese medicine are the cornerstone for building a large enterprise health industry platform, and will increasingly influence the future direction of the development of modern traditional Chinese medicine in China.

Company Profile

Symbol03737
Company NameZHONGZHIPHARM
ISINKYG989611085
Listing DateJul 13, 2015
Issue Price2.46
Shares Offered200.00M share(s)
FoundedSep 12, 2014
Registered AddressCayman Islands
Chairmanzhitian lai
Secretaryyongxin he
Audit InstitutionErnst & Young
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeWindward 3, Regatta Office Park PO Box 1350 Grand Cayman KY1-1108 Cayman Islands
Head Office and Principal Place of BusinessRoom 10B, 15th floor, Cable TV Tower, 9 Hoi Shing Road, Tsuen Wan, New Territories, Hong Kong
Fiscal Year Ends12-31
Employees2736
MarketHong Kong motherboard
Phone0760-85331222
Fax0760-85318764
Emailhr@zeus.cn
Business Zhongzhi Pharmaceutical Holdings Co., Ltd. is a Chinese investment holding company. The company is mainly engaged in R&D, manufacturing and sales of proprietary Chinese medicines and tablets (including traditional and novel tablets). The company operates through three divisions: the pharmaceutical division, the operation of a pharmacy chain in Zhongshan, Guangdong Province, and the operation of an online pharmacy. The company's brands include Zhongzhi, Liumian, and Caojinghua. The company mainly operates within China.

Company Executives

  • Name
  • Position
  • Salary
  • zhitian lai
  • Chairman of the Board, Executive Director, Remuneration Committee Members, Nomination Committee Members
  • 1.92M
  • yingfeng lai
  • CEO, Executive Director, Remuneration Committee Members, Nominate Remuneration Committee Members, Authorized Representative
  • 1.39M
  • yingsheng lai
  • Executive Director, Chief Financial Officer
  • 1.16M
  • xiaojun cao
  • Executive Director, Deputy General Manager
  • 1.36M
  • lixia jiang
  • Non-executive Directors
  • 270.00K
  • guanyun wu
  • Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members, Remuneration Committee Members
  • 162.00K
  • jinhua huang
  • Independent Non-Executive Director, Chairman of the Nomination Committee, Remuneration Committee Chairman, Audit Committee Members
  • 162.00K
  • daihan zhou
  • Independent Non-Executive Director, Audit Committee Members, Nomination Committee Members, Remuneration Committee Members
  • 162.00K
  • weilin qiao
  • Vice President of Zhongzhi Pharmaceutical Group
  • --
  • guiquan he
  • Group Vice President
  • --
  • qiang ran
  • Group Vice President
  • --
  • manna shen
  • General Manager of Zhongzhi Chain
  • --
  • jiong chen
  • General Manager of Hang Seng Pharmaceuticals
  • --
  • lin tang
  • Head of Technical Department of Zhongzhi Pharmaceutical and Chief Engineer of Hang Seng Pharmaceutical
  • --
  • yongxin he
  • Authorized Representative, Company Secretary
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data